Ultragenyx (RARE) sets 2033 date for Esjay’s generic DOJOLVI under patent settlement
Rhea-AI Filing Summary
Ultragenyx Pharmaceutical Inc. reports that it and Baylor Research Institute entered into a settlement agreement with Esjay Pharma regarding patent litigation over DOJOLVI® (triheptanoin) oral liquid. Esjay had filed an Abbreviated New Drug Application seeking approval to market a generic DOJOLVI in the United States.
Under the settlement, Ultragenyx will grant Esjay a non-exclusive, royalty-free license to market its generic version of DOJOLVI starting January 1, 2033, extendable to July 1, 2033 if pediatric exclusivity is granted, subject to customary conditions and exceptions. Similar litigation with other ANDA filers remains pending, and the agreement will be submitted to the FTC and Department of Justice.
Positive
- Settlement sets a clear earliest-entry date for generic DOJOLVI (January 1, 2033, or July 1, 2033 with pediatric exclusivity), reducing near- to medium-term patent uncertainty.
- The license to Esjay is described as non-exclusive and royalty-free, suggesting no ongoing royalty burden to Ultragenyx while resolving this specific DOJOLVI patent dispute.
Negative
- Agreement grants Esjay the right to market a generic DOJOLVI in the U.S. starting as early as January 1, 2033, indicating future generic competition after that date.
- Similar patent litigation with other ANDA filers remains pending, so overall DOJOLVI patent-related legal exposure has not been fully resolved.
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Generic entry date: January 1, 2033
Extended generic entry date with pediatric exclusivity: July 1, 2033
Settlement date: August 7, 2026
3 metrics
Generic entry date
January 1, 2033
Earliest date Esjay may market its generic DOJOLVI under the license
Extended generic entry date with pediatric exclusivity
July 1, 2033
Date from which Esjay may market generic DOJOLVI if DOJOLVI receives pediatric exclusivity
Settlement date
August 7, 2026
Date Ultragenyx and Baylor Research Institute entered into the settlement with Esjay
Key Terms
Abbreviated New Drug Application, pediatric exclusivity, non-exclusive, royalty-free license, ANDA filers
4 terms
Abbreviated New Drug Application regulatory
"resulted from submission by Esjay of an Abbreviated New Drug Application"
An abbreviated new drug application is a regulatory submission used to gain approval to market a generic version of an already approved prescription medicine by showing it is equivalent in effect and safety to the original product, without repeating full clinical trials. For investors, an approval signals a lower-cost competitor entering the market that can quickly capture sales from the branded drug, similar to a generic knock‑off replacing a name‑brand item on store shelves.
pediatric exclusivity regulatory
"extended to July 1, 2033 if pediatric exclusivity is granted for DOJOLVI"
Pediatric exclusivity is a regulatory reward that gives a drug maker extra protected selling time—typically a six‑month extension—if the company conducts studies showing the medicine is safe and effective for children. For investors, it matters because that extra time is like a temporary shield that delays generic competition and can materially extend revenue from a product, affecting a drug’s cash flow, valuation and investment returns.
non-exclusive, royalty-free license financial
"the Company will grant Esjay a non-exclusive, royalty-free license to market its generic"
ANDA filers regulatory
"Similar patent litigation brought by the Company against other ANDA filers related to DOJOLVI"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Ultragenyx (RARE) announce regarding DOJOLVI patent litigation?
Ultragenyx disclosed a settlement with Esjay Pharma resolving patent litigation over DOJOLVI (triheptanoin) oral liquid. The dispute arose from Esjay’s ANDA filing to market a generic DOJOLVI in the United States.
When can Esjay start selling generic DOJOLVI under the Ultragenyx (RARE) settlement?
Esjay may market its generic DOJOLVI under a license starting January 1, 2033. This start date is extended to July 1, 2033 if DOJOLVI receives pediatric exclusivity, subject to conditions in the agreement.
What are the key terms of Ultragenyx’s license to Esjay for generic DOJOLVI?
Ultragenyx will grant Esjay a non-exclusive, royalty-free license to sell generic DOJOLVI beginning January 1, 2033, or July 1, 2033 with pediatric exclusivity, with conditions and exceptions customary for such patent settlement agreements.
Does the Ultragenyx (RARE) settlement end all DOJOLVI patent litigation?
No. The settlement resolves litigation with Esjay Pharma only. Ultragenyx states that similar patent litigation against other ANDA filers related to DOJOLVI remains pending in the U.S. District Court for the District of New Jersey.
Will regulators review the Ultragenyx–Esjay DOJOLVI settlement?
Yes. Ultragenyx states that the settlement agreement will be submitted to the Federal Trade Commission and the Department of Justice, as required by law for certain pharmaceutical patent settlements.